FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2944282314> ?p ?o ?g. }

• W2944282314 endingPage "1404" @default.
• W2944282314 startingPage "1394" @default.
• W2944282314 abstract "ETNA-VTE-Japan is an ongoing prospective observational study conducted as part of a postmarketing observational study to investigate the safety and effectiveness of edoxaban in Japanese patients for whom the drug has been newly prescribed to treat venous thromboembolism (VTE) and prevent VTE recurrence. The results of an interim analysis of data collected at 3 months are presented.Methods and Results:A total of 1,732 patients were enrolled. The safety and effectiveness analyses included data from 1,703 and 1,699 patients, respectively. In the safety analysis set, 39.4% of patients were aged ≥75 years, 58.2% had body weight ≤60 kg, and 22.2% had creatinine clearance <50 mL/min. Approximately 90% of patients received a dose in accordance with the package insert. Approximately 80% of patients continued treatment; the mean treatment period was 74.5 days. The incidence of bleeding adverse events and major bleeding was 6.3% and 1.4%, respectively. The incidence of VTE recurrence and symptomatic VTE recurrence in the on-treatment population was 0.8% and 0.4%, respectively. Safety and effectiveness profiles of edoxaban in patients receiving the low dose (30 mg/day), generally administered to patients with high bleeding risk, were similar to those of the standard dose (60 mg/day).The results confirm no major concerns about the safety and effectiveness of edoxaban in Japanese patients with VTE in the first 3 months of treatment. (Trial registration No.: UMIN000016387.)." @default.
• W2944282314 created "2019-05-16" @default.
• W2944282314 creator A5004599472 @default.
• W2944282314 creator A5012328320 @default.
• W2944282314 creator A5018957695 @default.
• W2944282314 creator A5021117400 @default.
• W2944282314 creator A5031675044 @default.
• W2944282314 date "2019-05-24" @default.
• W2944282314 modified "2023-10-12" @default.
• W2944282314 title "Safety and Effectiveness of Edoxaban in Japanese Patients With Venous Thromboembolism ― An Interim Analysis of Data From a Japanese Postmarketing Observational Study (ETNA-VTE-Japan) ―" @default.
• W2944282314 cites W1681417486 @default.
• W2944282314 cites W1808477918 @default.
• W2944282314 cites W1973598884 @default.
• W2944282314 cites W2008955498 @default.
• W2944282314 cites W2018856451 @default.
• W2944282314 cites W2023634900 @default.
• W2944282314 cites W2027735039 @default.
• W2944282314 cites W2115019673 @default.
• W2944282314 cites W2115273341 @default.
• W2944282314 cites W2115787552 @default.
• W2944282314 cites W2130199362 @default.
• W2944282314 cites W2135583595 @default.
• W2944282314 cites W2160625453 @default.
• W2944282314 cites W2166402206 @default.
• W2944282314 cites W2311109719 @default.
• W2944282314 cites W2415511892 @default.
• W2944282314 cites W2492552840 @default.
• W2944282314 cites W2566947560 @default.
• W2944282314 cites W2592934015 @default.
• W2944282314 cites W2606507895 @default.
• W2944282314 cites W2622276831 @default.
• W2944282314 cites W2731095182 @default.
• W2944282314 cites W2765412569 @default.
• W2944282314 cites W2792827296 @default.
• W2944282314 cites W4230696091 @default.
• W2944282314 cites W4296148784 @default.
• W2944282314 doi "https://doi.org/10.1253/circj.cj-18-1362" @default.
• W2944282314 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31080193" @default.
• W2944282314 hasPublicationYear "2019" @default.
• W2944282314 type Work @default.
• W2944282314 sameAs 2944282314 @default.
• W2944282314 citedByCount "7" @default.
• W2944282314 countsByYear W29442823142019 @default.
• W2944282314 countsByYear W29442823142020 @default.
• W2944282314 countsByYear W29442823142022 @default.
• W2944282314 countsByYear W29442823142023 @default.
• W2944282314 crossrefType "journal-article" @default.
• W2944282314 hasAuthorship W2944282314A5004599472 @default.
• W2944282314 hasAuthorship W2944282314A5012328320 @default.
• W2944282314 hasAuthorship W2944282314A5018957695 @default.
• W2944282314 hasAuthorship W2944282314A5021117400 @default.
• W2944282314 hasAuthorship W2944282314A5031675044 @default.
• W2944282314 hasBestOaLocation W29442823141 @default.
• W2944282314 hasConcept C120665830 @default.
• W2944282314 hasConcept C121332964 @default.
• W2944282314 hasConcept C126322002 @default.
• W2944282314 hasConcept C141071460 @default.
• W2944282314 hasConcept C166957645 @default.
• W2944282314 hasConcept C194828623 @default.
• W2944282314 hasConcept C197636746 @default.
• W2944282314 hasConcept C197934379 @default.
• W2944282314 hasConcept C23131810 @default.
• W2944282314 hasConcept C2776301958 @default.
• W2944282314 hasConcept C2776957806 @default.
• W2944282314 hasConcept C2778661090 @default.
• W2944282314 hasConcept C2779161974 @default.
• W2944282314 hasConcept C2780290652 @default.
• W2944282314 hasConcept C2780868729 @default.
• W2944282314 hasConcept C2991741193 @default.
• W2944282314 hasConcept C535046627 @default.
• W2944282314 hasConcept C61511704 @default.
• W2944282314 hasConcept C61943457 @default.
• W2944282314 hasConcept C71924100 @default.
• W2944282314 hasConcept C95457728 @default.
• W2944282314 hasConceptScore W2944282314C120665830 @default.
• W2944282314 hasConceptScore W2944282314C121332964 @default.
• W2944282314 hasConceptScore W2944282314C126322002 @default.
• W2944282314 hasConceptScore W2944282314C141071460 @default.
• W2944282314 hasConceptScore W2944282314C166957645 @default.
• W2944282314 hasConceptScore W2944282314C194828623 @default.
• W2944282314 hasConceptScore W2944282314C197636746 @default.
• W2944282314 hasConceptScore W2944282314C197934379 @default.
• W2944282314 hasConceptScore W2944282314C23131810 @default.
• W2944282314 hasConceptScore W2944282314C2776301958 @default.
• W2944282314 hasConceptScore W2944282314C2776957806 @default.
• W2944282314 hasConceptScore W2944282314C2778661090 @default.
• W2944282314 hasConceptScore W2944282314C2779161974 @default.
• W2944282314 hasConceptScore W2944282314C2780290652 @default.
• W2944282314 hasConceptScore W2944282314C2780868729 @default.
• W2944282314 hasConceptScore W2944282314C2991741193 @default.
• W2944282314 hasConceptScore W2944282314C535046627 @default.
• W2944282314 hasConceptScore W2944282314C61511704 @default.
• W2944282314 hasConceptScore W2944282314C61943457 @default.
• W2944282314 hasConceptScore W2944282314C71924100 @default.
• W2944282314 hasConceptScore W2944282314C95457728 @default.
• W2944282314 hasIssue "6" @default.
• W2944282314 hasLocation W29442823141 @default.
• W2944282314 hasLocation W29442823142 @default.

• next